FDA Launches DSCSA Pilot Projects: What Wholesale Distributors Need to Know

The FDA announced on January 14, 2025 that it will launch a series of pilot projects under the Drug Supply Chain Security Act (DSCSA) to test interoperable tracing systems before finalizing enforcement requirements for wholesale drug distributors. The agency is seeking participation from distributors, manufacturers, and dispensers to validate serialization, verification, and transaction data exchange systems ahead of the November 27, 2027 product tracing deadline.

Regulatory Background

The DSCSA, enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established requirements for an electronic, interoperable system to identify and trace prescription drugs as they move through the U.S. supply chain. Under 21 CFR 582, wholesale drug distributors must verify product identifiers, maintain transaction information, and provide tracing data upon FDA request.

The statute's product tracing requirements take full effect November 27, 2027. At that point, distributors must be able to trace a product at the package level through the supply chain, respond to FDA verification requests within 24 hours for suspect products and 48 hours for illegitimate products, and exchange standardized Electronic Product Code Information Services (EPCIS) data with trading partners.

Current enforcement policy under the November 27, 2023 compliance date applies to transaction information, transaction history, and transaction statements (TI/TH/TS), along with product identifier verification for saleable returns. The pilot projects are intended to identify technical, operational, and policy challenges before the final tracing requirements become enforceable.

Pilot Project Structure

FDA's announcement outlines three pilot categories, each testing different components of the interoperable tracing system:

1. Verification Routing Service (VRS) pilots — Testing how distributors query product identifier data across multiple manufacturer systems. VRS is intended to solve the problem of distributors needing to connect to hundreds of manufacturer verification endpoints individually.

1. Enhanced drug distribution security pilots — Testing serialization workflows for scenarios the statute requires but industry has not yet standardized: product aggregation, case-level handling, and exception management for damaged or repackaged products.

1. Interoperable data exchange pilots — Testing EPCIS 2.0 messaging standards between trading partners, including how distributors exchange Authorized Trading Partner (ATP) credentials, saleable returns data, and suspect product notifications.

Participation is voluntary. FDA will not take enforcement action based on pilot results. Entities that participate will submit technical findings to the agency by July 2026. FDA will use pilot data to issue updated compliance guidance by December 2026 — one year before full enforcement begins.

Impact on Wholesale Drug Distributors

Distributors in ColdChainCheck's directory should evaluate whether participation in a pilot project aligns with their compliance readiness timeline. Key operational considerations:

VRS integration requirements — Distributors already querying manufacturer verification systems will need to test whether their current middleware supports VRS routing. Entities without verification infrastructure in place may need to select a solution provider before pilot participation is feasible.

EPCIS data format validation — The FDA explicitly references EPCIS 2.0 as the required standard. Distributors using legacy EDI formats for transaction data will need to implement EPCIS before the 2027 deadline. Pilot projects offer an opportunity to test EPCIS message formats with actual trading partners under FDA observation, reducing risk of non-compliance later.

Saleable returns serialization — The statute requires verification of product identifiers on saleable returns. Many distributors' current workflows do not capture package-level serial numbers at inbound receiving. Pilot participation would validate whether existing WMS systems can handle serialized returns processing without manual intervention.

Regulatory signal for enforcement priorities — FDA's choice of pilot categories indicates where the agency expects compliance gaps. Distributors that cannot demonstrate VRS connectivity, EPCIS messaging capability, and serialized returns handling by mid-2026 should expect those areas to be enforcement focus points after November 2027.

The application period for pilot participation closes March 15, 2025. Distributors interested in participating must submit a letter of intent through FDA's DSCSA pilot portal, including a description of their current serialization and tracing infrastructure.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration — a baseline requirement for DSCSA compliance. However, FDA registration alone does not indicate serialization or EPCIS readiness.

The average compliance score in ColdChainCheck's directory is 51/100, placing the majority of tracked entities in the "Fair" tier. This score reflects verified licensure, accreditation, and regulatory history — but does not yet include DSCSA-specific infrastructure verification. Only 63 entities hold NABP Accredited Wholesale Distributor (formerly VAWD) status, which includes standards for transaction documentation and record-keeping systems, though it predates full serialization requirements.

The score distribution suggests readiness variance: 28 entities (2.2%) score in the "Excellent" range (75-100 points), while 919 entities (72.1%) fall into "Fair" (40-59 points). Entities in the Fair tier typically have active state licenses and FDA registration but limited third-party verification signals. This distribution indicates that a significant portion of the wholesale distributor community may lack the infrastructure to participate in FDA's pilot projects without additional investment.

Practical Steps for Compliance Teams

• Verify trading partner FDA registration status — Use the ColdChainCheck directory to confirm current FDA establishment registration for distributors in your supply chain. Entities without active registration are not eligible for pilot participation and face baseline compliance gaps before serialization requirements apply.

• Check for regulatory enforcement history — ColdChainCheck tracks 73 entities with FDA recalls or warning letters on record. Review whether your current distributors appear in this subset. Entities with recent enforcement actions may face additional scrutiny if they apply for pilot participation.

• Monitor NABP accreditation status — The 63 NABP-accredited entities in ColdChainCheck's directory represent distributors with verified transaction documentation systems. If your current trading partners lack NABP accreditation, confirm they have alternative verification systems in place that support EPCIS data exchange.

• Document due diligence before November 2027 — QA teams should begin building audit trails now. Use ColdChainCheck to pull verified license and registration data for each trading partner, then request DSCSA readiness attestations directly. Documented verification requests made in 2025-2026 will support compliance demonstrations if FDA enforcement begins in late 2027.

ColdChainCheck will continue tracking DSCSA-related enforcement actions and pilot project outcomes as they become public record. See the DSCSA compliance checklist for detailed coverage of product tracing requirements and verification workflows.

Disclaimer: This article provides general informational content based on publicly available regulatory announcements and ColdChainCheck directory data. It does not constitute legal or compliance advice. Verify all regulatory requirements with the FDA and your legal counsel.